✦ LIBER ✦

Anti-tumor necrosis factor alpha treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis

✍ Scribed by Georgia Avgerinou; Dimitris Tousoulis; Gerasimos Siasos; Evaggelos Oikonomou; Konstantinos Maniatis; Nikolaos Papageorgiou; Theodoros Paraskevopoulos; Antigoni Miliou; Dimitra Koumaki; George Latsios; Anastasia Therianiou; Athanasios Trikas; Anna Maria Kampoli; Christodoulos Stefanadis

Book ID: 116550173
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 134 KB
Volume: 151
Category: Article
ISSN: 0167-5273
DOI: 10.1016/j.ijcard.2011.06.112

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Anti-Tumor Necrosis Factor-alpha Treatme

Anti-Tumor Necrosis Factor-alpha Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis

✍ Hurlimann, D. 📂 Article 📅 2002 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 326 KB

PSY16 Effect of the Anti-Tumor Necrosis

PSY16 Effect of the Anti-Tumor Necrosis Factor Adalimumab on Work Productivity in Patients With Chronic Immune-Mediated Inflammatory Diseases: Literature Review

✍ Granados, D.; Depont, F.; Chevreul, K. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Active but transient improvement of endo

Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor α antibody

✍ Gonzalez-Juanatey, Carlos ;Testa, Ana ;Garcia-Castelo, Alberto ;Garcia-Porrua, C 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 2 views

## Abstract ## Objective Cardiovascular disease is the major cause of excessive mortality in rheumatoid arthritis (RA). Atherosclerosis and RA share similar inflammatory mechanisms that include involvement of tumor necrosis factor α (TNFα). Anti‐TNFα antibody improved endothelial function in RA pa

Radiographic, clinical, and functional o

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial

✍ Edward C. Keystone; Arthur F. Kavanaugh; John T. Sharp; Hyman Tannenbaum; Ye Hua 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB 👁 2 views